In company news, declines for shares of Cumberland Pharmaceuticals ( CPIX ) were picking up speed Tuesday afternoon, with the generics drugmaker receiving little apparent traction from its announcement last night that its Caldolor medication has been approved by Australian regulators for reducing pain and fever in adults. CPIX shares were down almost 4% at $5.62 each this afternoon, matching their session low. H.C. Wainwright reiterates Buy rating and increases price target from 11 cents to $11 a share, reflecting AEZS's Nov. 18 100-for-1 reverse stock split.